A variety of strategies targeting key glycolytic genes (such as GLUT1, HK2, PK, etc.)can induce tumor cell death or enhance anti-tumor immunity by reducing ATP production and triggering mitochondrial damage. This evidence concerns the gene SLC2A1 and neoplasm.